Improving Healthcare Through Research: A Fireside Chat With The All Of Us Research Program

Julia Moore Vogel, PhD is a Program Director at Scripps Research. She manages The Participant Center (TPC) for the NIH-funded All of Us Research Program. TPC is charged with recruiting and retaining 350,000 individuals that represent the diversity of the United States and aims to make it possible for interested individuals anywhere in the US to become active participants, for example by collaborating with numerous outreach partners to raise awareness, collecting biosamples nationwide, returning participants’ results and developing self-guided workflows that enable participants to join whenever is convenient for them. Participants’ information is shared with them and made available to researchers who aim to make medical breakthroughs. She is also using her two years of lived experience with Long COVID to study the effectiveness of wrist-worn wearable devices and educational materials in decreasing Long COVID symptom severity. 

Prior to SRTI, Julia created, proposed, fundraised for, and implemented research and clinical genomics initiatives at the New York Genome Center and The Rockefeller University. She oversaw the proposal and execution of grants, including a $44M NIH Center for Common Disease Genomics in collaboration with over 20 scientific contributors across seven institutions. She also managed corporate partnerships, including one that assessed the relative value of several genomic assays for cancer patients. She has a BS in Mathematics from RPI, PhD in Computational Biology and Medicine from Cornell and MBA from Cornell. 
 

Sanjay J. Mathew, M.D. is the Marjorie Bintliff Johnson and Raleigh White Johnson, Jr. Vice Chair for Research and Professor in the Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine. He is also a staff psychiatrist at the Michael E. Debakey VA Medical Center (MEDVAMC) in Houston, Texas. He graduated from Dartmouth College and Baylor College of Medicine, and trained in psychiatry at Columbia University and the New York State Psychiatric Institute, where he also completed a NIH-funded research fellowship in affective and anxiety disorders. Dr. Mathew began his faculty career at the Icahn School of Medicine at Mount Sinai where he co-founded and directed the Mood & Anxiety Disorders Program. In 2010, Dr. Mathew was recruited back to his hometown of Houston to direct Baylor’s Mood & Anxiety Disorders Program. His research program focuses on developing novel therapies for patients with treatment-resistant mood and anxiety disorders and PTSD, with a particular focus on rapid-acting glutamate-modulating agents. 

Dr. Mathew’s research program has been funded by NIMH, Department of Veterans Affairs, Patient-Centered Outcomes Research Institute (PCORI), and industry in the areas of experimental therapeutics and pathophysiology of treatment-resistant depression, suicide, and PTSD. He has authored or co-authored over 130 manuscripts and book chapters, and serves on the editorial board of several journals. In addition to his long involvement with ADAA including serving as Chair of the Program Committee (2017-2018), Dr. Mathew is a member of the American College of Neuropsychopharmacology, and board member of the American Society of Clinical Psychopharmacology. Dr. Mathew is ADAA Chief Medical Officer and Board Secretary. An active clinician and teacher, Dr. Mathew has been selected by his peers as a “Best Doctor” every year since 2011, and has received awards for his teaching of psychopharmacology.

"I am excited to have the opportunity to serve as President-Elect of ADAA, a professional membership organization truly committed to its education, practice, and research missions.   I look forward to collaborating with Dr. Simpson, the Board of Directors, and the ADAA staff to further strengthen the impact and reach of our organization for patients who suffer from these common and often debilitating conditions."